Several other research analysts have also recently issued reports on MNK. Morgan Stanley cut their target price on shares of Mallinckrodt from $40.00 to $27.00 and set an equal weight rating on the stock in a report on Wednesday, November 8th. Cantor Fitzgerald set a $42.00 target price on shares of Mallinckrodt and gave the stock a buy rating in a report on Tuesday. BMO Capital Markets cut their target price on shares of Mallinckrodt to $38.00 and set an outperform rating on the stock in a report on Wednesday, November 8th. Barclays cut shares of Mallinckrodt from an overweight rating to an equal weight rating and cut their target price for the stock from $65.00 to $23.00 in a report on Wednesday, November 8th. Finally, Leerink Swann assumed coverage on shares of Mallinckrodt in a report on Tuesday, January 2nd. They issued a market perform rating and a $26.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company. Mallinckrodt currently has a consensus rating of Hold and a consensus target price of $42.64.
Mallinckrodt (NYSE MNK) opened at $18.66 on Tuesday. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 1.08. Mallinckrodt has a fifty-two week low of $15.27 and a fifty-two week high of $54.64. The stock has a market cap of $1,538.13, a P/E ratio of 5.04, a PEG ratio of 0.30 and a beta of 1.04.
A number of large investors have recently added to or reduced their stakes in MNK. Macquarie Group Ltd. lifted its position in Mallinckrodt by 62.7% during the fourth quarter. Macquarie Group Ltd. now owns 58,422 shares of the company’s stock valued at $9,069,000 after buying an additional 22,507 shares during the period. LPL Financial LLC purchased a new position in Mallinckrodt during the fourth quarter valued at $1,718,000. Sciencast Management LP purchased a new position in Mallinckrodt during the fourth quarter valued at $210,000. Two Sigma Investments LP purchased a new position in Mallinckrodt during the fourth quarter valued at $30,841,000. Finally, Two Sigma Advisers LP purchased a new position in Mallinckrodt during the fourth quarter valued at $24,007,000. Institutional investors and hedge funds own 97.38% of the company’s stock.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.